This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Reports Third Quarter 2011 Financial Results

For the nine-month period ending September 30, 2011, Curis reported a net loss of $15.9 million, or ($0.21) per share on both a basic and fully diluted shares outstanding basis, as compared to net income of $1.2 million or $0.02 per share on both a basic and fully diluted shares outstanding basis for the same period in 2010.

Revenues for the nine months ended September 30, 2011, were $700,000 as compared to $15.9 million for the same period in 2010. This decrease is primarily the result of $11.3 million in license fee revenue that was recorded during the nine months ended September 30, 2010 as a result of milestone payments that Curis received from Debiopharm during such period. During the prior year period, Curis also received proceeds of $4.0 million pursuant to a settlement agreement that the Company entered into with a former collaborator in February 2010. No license fee revenue was recorded under Curis’ ongoing collaborations with Genentech and Debiopharm for the nine months ended September 30, 2011.

Operating expenses were $15.4 million for the nine months ended September 30, 2011, as compared to $15.9 million for the same period in 2010. Research and development expenses were $9.2 million for the nine months ended September 30, 2011, as compared to $7.7 million for the same period in 2010. General and administrative expenses were $6.2 million for the nine months ended September 30, 2011, as compared to $8.2 million for the same period in 2010.

Other expense was $1.2 million for the nine-month period ended September 30, 2011, as compared to other income of $1.2 million for the same period in 2010.

As of September 30, 2011, Curis’ cash, cash equivalents and marketable securities totaled $28.4 million, and there were 76.6 million shares of common stock outstanding.

Recent Developments

-- Genentech Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)

In September 2011, Curis’ collaborator Genentech, a member of the Roche group, submitted a New Drug Application (NDA) to the FDA seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC patients for whom surgery is considered inappropriate. Curis is eligible to receive an $8 million milestone payment from Genentech upon FDA acceptance of this submission. If the drug receives FDA approval, then Curis will also be entitled to receive an additional milestone payment as well as royalties on any future sales.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs